Cargando…
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for a third dose of vaccine. We evaluated early safety and immunogenicity after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Journal Experts
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094107/ https://www.ncbi.nlm.nih.gov/pubmed/35547849 http://dx.doi.org/10.21203/rs.3.rs-1222037/v1 |
| _version_ | 1784705471075057664 |
|---|---|
| author | Anderson, Evan Jackson, Lisa Rouphael, Nadine Widge, Alicia Montefiori, David Doria-Rose, Nicole Suthar, Mehul Cohen, Kristen O’Connell, Sarah Makowski, Mat Makhene, Mamodikoe Buchanan, Wendy Spearman, Paul Creech, C. Buddy O’Dell, Sijy Schmidt, Stephen Leav, Brett Bennett, Hamilton Pajon, Rolando Posavad, Christine Hural, John Beigel, John Albert, Jim Abebe, Kuleni Eaton, Amanda Rostad, Christina Rebolledo, Paulina Kamidani, Satoshi Graciaa, Daniel Coler, Rhea McDermott, Adrian Ledgerwood, Julie Mascola, John DeRosa, Stephen Neuzil, Kathleen McElrath, M. Juliana Roberts, Paul |
| author_facet | Anderson, Evan Jackson, Lisa Rouphael, Nadine Widge, Alicia Montefiori, David Doria-Rose, Nicole Suthar, Mehul Cohen, Kristen O’Connell, Sarah Makowski, Mat Makhene, Mamodikoe Buchanan, Wendy Spearman, Paul Creech, C. Buddy O’Dell, Sijy Schmidt, Stephen Leav, Brett Bennett, Hamilton Pajon, Rolando Posavad, Christine Hural, John Beigel, John Albert, Jim Abebe, Kuleni Eaton, Amanda Rostad, Christina Rebolledo, Paulina Kamidani, Satoshi Graciaa, Daniel Coler, Rhea McDermott, Adrian Ledgerwood, Julie Mascola, John DeRosa, Stephen Neuzil, Kathleen McElrath, M. Juliana Roberts, Paul |
| author_sort | Anderson, Evan |
| collection | PubMed |
| description | Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for a third dose of vaccine. We evaluated early safety and immunogenicity after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9 to 10 months earlier. The booster vaccine formulations included 100 mcg of mRNA-1273, 50 mcg of mRNA-1273.351 that encodes Beta variant spike protein, and bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351. A third dose of mRNA vaccine appeared safe with acceptable reactogenicity. Vaccination induced rapid increases in binding and neutralizing antibody titers to D614G, Beta, and Delta variants that were similar or greater than peak responses after the second dose. Spike-specific CD4+ and CD8+ T cells increased to similar levels as after the second dose. A third mRNA vaccination was well tolerated and generated robust humoral and T cell responses. ClinicalTrials.gov numbers NCT04283461 (mRNA-1273 Phase 1) and NCT04785144 (mRNA-1273.351 Phase 1) |
| format | Online Article Text |
| id | pubmed-9094107 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Journal Experts |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90941072022-05-12 Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis Anderson, Evan Jackson, Lisa Rouphael, Nadine Widge, Alicia Montefiori, David Doria-Rose, Nicole Suthar, Mehul Cohen, Kristen O’Connell, Sarah Makowski, Mat Makhene, Mamodikoe Buchanan, Wendy Spearman, Paul Creech, C. Buddy O’Dell, Sijy Schmidt, Stephen Leav, Brett Bennett, Hamilton Pajon, Rolando Posavad, Christine Hural, John Beigel, John Albert, Jim Abebe, Kuleni Eaton, Amanda Rostad, Christina Rebolledo, Paulina Kamidani, Satoshi Graciaa, Daniel Coler, Rhea McDermott, Adrian Ledgerwood, Julie Mascola, John DeRosa, Stephen Neuzil, Kathleen McElrath, M. Juliana Roberts, Paul Res Sq Article Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for a third dose of vaccine. We evaluated early safety and immunogenicity after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9 to 10 months earlier. The booster vaccine formulations included 100 mcg of mRNA-1273, 50 mcg of mRNA-1273.351 that encodes Beta variant spike protein, and bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351. A third dose of mRNA vaccine appeared safe with acceptable reactogenicity. Vaccination induced rapid increases in binding and neutralizing antibody titers to D614G, Beta, and Delta variants that were similar or greater than peak responses after the second dose. Spike-specific CD4+ and CD8+ T cells increased to similar levels as after the second dose. A third mRNA vaccination was well tolerated and generated robust humoral and T cell responses. ClinicalTrials.gov numbers NCT04283461 (mRNA-1273 Phase 1) and NCT04785144 (mRNA-1273.351 Phase 1) American Journal Experts 2022-05-03 /pmc/articles/PMC9094107/ /pubmed/35547849 http://dx.doi.org/10.21203/rs.3.rs-1222037/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/) |
| spellingShingle | Article Anderson, Evan Jackson, Lisa Rouphael, Nadine Widge, Alicia Montefiori, David Doria-Rose, Nicole Suthar, Mehul Cohen, Kristen O’Connell, Sarah Makowski, Mat Makhene, Mamodikoe Buchanan, Wendy Spearman, Paul Creech, C. Buddy O’Dell, Sijy Schmidt, Stephen Leav, Brett Bennett, Hamilton Pajon, Rolando Posavad, Christine Hural, John Beigel, John Albert, Jim Abebe, Kuleni Eaton, Amanda Rostad, Christina Rebolledo, Paulina Kamidani, Satoshi Graciaa, Daniel Coler, Rhea McDermott, Adrian Ledgerwood, Julie Mascola, John DeRosa, Stephen Neuzil, Kathleen McElrath, M. Juliana Roberts, Paul Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title_full | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title_fullStr | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title_full_unstemmed | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title_short | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis |
| title_sort | safety and immunogenicity of a third dose of sars-cov-2 mrna vaccine – an interim analysis |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094107/ https://www.ncbi.nlm.nih.gov/pubmed/35547849 http://dx.doi.org/10.21203/rs.3.rs-1222037/v1 |
| work_keys_str_mv | AT andersonevan safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT jacksonlisa safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT rouphaelnadine safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT widgealicia safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT montefioridavid safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT doriarosenicole safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT sutharmehul safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT cohenkristen safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT oconnellsarah safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT makowskimat safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT makhenemamodikoe safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT buchananwendy safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT spearmanpaul safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT creechcbuddy safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT odellsijy safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT schmidtstephen safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT leavbrett safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT bennetthamilton safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT pajonrolando safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT posavadchristine safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT huraljohn safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT beigeljohn safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT albertjim safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT abebekuleni safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT eatonamanda safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT rostadchristina safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT rebolledopaulina safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT kamidanisatoshi safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT graciaadaniel safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT colerrhea safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT mcdermottadrian safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT ledgerwoodjulie safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT mascolajohn safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT derosastephen safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT neuzilkathleen safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT mcelrathmjuliana safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis AT robertspaul safetyandimmunogenicityofathirddoseofsarscov2mrnavaccineaninterimanalysis |